<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-9957</journal-id>
<journal-title><![CDATA[Revista colombiana de Gastroenterología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Col Gastroenterol]]></abbrev-journal-title>
<issn>0120-9957</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Gastroenterología  ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-99572007000400010</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento médico para enfermedad inflamatoria intestinal]]></article-title>
<article-title xml:lang="en"><![CDATA[Medical therapy for inflammatory bowel disease]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Juliao Baños]]></surname>
<given-names><![CDATA[Fabián]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Hospital Pablo Tobón Uribe Unidad de Gastroenterología ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>12</month>
<year>2007</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>12</month>
<year>2007</year>
</pub-date>
<volume>22</volume>
<numero>4</numero>
<fpage>313</fpage>
<lpage>330</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-99572007000400010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-99572007000400010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-99572007000400010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[El tratamiento médico óptimo de los pacientes con enfermedad inflamatoria intestinal requiere que el médico tratante obtenga una buena historia clínica, evalúe al paciente, realice los procedimientos diagnósticos necesarios, y luego prescriba un tratamiento adecuado, basado en la evidencia de estudios clínicos controlados. Las metas del tratamiento farmacológico en pacientes con enfermedad inflamatoria intestinal son mejorar la calidad de vida, reducir el riesgo de complicaciones y evitar intervenciones quirúrgicas. Las recomendaciones de la nueva clasificación de Montreal con respecto a enfermedad de Crohn y colitis ulcerativa deben ser implementadas en nuestra práctica clínica. Finalmente, la introducción de la terapia biológica (Infliximab, adalimumab) ha mejorado las opciones de tratamiento en el manejo de la enfermedad inflamatoria intestinal.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[The optimal medical treatment of patients with inflammatory bowel disease requires that the treating physician obtain a good history, evaluate the patient, perform necessary diagnostic procedures, and then prescribe an appropriate treatment based in the evidence from controlled clinical trials. The goals of pharmacology treatment in patients with inflammatory bowel disease are to improve quality of life, reduce the risk of complications and avoid surgical interventions. The recommendations of the new Montreal classification with respect to Crohn`s Disease and Ulcerative Colitis might be used in our clinical practice. Finally, the introduction of biological therapy (Infliximab, adalimumab), has greatly improved the treatment options in the management of inflammatory bowel disease.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermedad inflamatoria intestinal]]></kwd>
<kwd lng="es"><![CDATA[colitis ulcerativa]]></kwd>
<kwd lng="es"><![CDATA[enfermedad de Crohn]]></kwd>
<kwd lng="es"><![CDATA[clasificación de Montreal]]></kwd>
<kwd lng="es"><![CDATA[terapia biológica]]></kwd>
<kwd lng="en"><![CDATA[Inflammatory Bowel Disease]]></kwd>
<kwd lng="en"><![CDATA[Crohn`s Disease]]></kwd>
<kwd lng="en"><![CDATA[Ulcerative Colitis]]></kwd>
<kwd lng="en"><![CDATA[Montreal classification]]></kwd>
<kwd lng="en"><![CDATA[biological therapy]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[  ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Satsangi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Vermeire]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Colombel]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2006</year>
<volume>55</volume>
<page-range>749-753</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Langolz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Munkholm]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Davidsen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Course of ulcerative colitis: analyses of changes in disease activity over years]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>1994</year>
<volume>107</volume>
<page-range>3-11</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sartor]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Medical Therapy for Crohn´s disease]]></article-title>
<source><![CDATA[Kirsner´s Inflammatory Bowel Disease]]></source>
<year>2004</year>
<volume>34</volume>
<page-range>531-554</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Management of Crohn´s disease in adults]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2001</year>
<volume>96</volume>
<page-range>635-643</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cammá]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Giunta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rosselli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cottone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mesalamine in the maintenance treatment of Crohn’s Disease: A meta-analysis adjusted for confounding variables]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>1997</year>
<volume>113</volume>
<page-range>1465-1473</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lochs]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mayer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prophylaxis of postoperative relapse in Crohn´s Disease with mesalamine: European Cooperative Crohn´s Disease study IV]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2000</year>
<volume>118</volume>
<page-range>264-273</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Akobeng]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Gardener]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn´s Disease]]></article-title>
<source><![CDATA[Cochrane database of systematic reviews]]></source>
<year>2005</year>
<volume>1</volume>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kane]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Schoenfeld]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tremaine]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Feagan]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Systematic review: the effectiveness of budesonide therapy for Crohn´s disease]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2002</year>
<volume>16</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1509-1517</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simms]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Steinhart]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Budesonide for maintenance of remission in Crohn´s disease]]></article-title>
<source><![CDATA[Cochrane database of systematic reviews]]></source>
<year>2001</year>
<volume>1</volume>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faubion]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Loftus]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The natural history of corticosteroids therapy for inflammatory bowel disease: a population-based study]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2001</year>
<volume>121</volume>
<page-range>255-60</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aberra]]></surname>
<given-names><![CDATA[FN]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtenstein]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Review article: monitoring of immunomodulators in inflammatory bowel disease]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2005</year>
<volume>21</volume>
<page-range>307-319</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sutherland]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Azathioprine or 6-mercaptopurine for induction of remission in Crohn´s disease]]></article-title>
<source><![CDATA[Cochrane database of systematic reviews]]></source>
<year>1998</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[May]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Sutherland]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Azathioprine for maintenance of remission in Crohn´s disease]]></article-title>
<source><![CDATA[Cochrane database of systematic reviews]]></source>
<year>1998</year>
<volume>4</volume>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kandiel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fraser]]></surname>
<given-names><![CDATA[A G]]></given-names>
</name>
<name>
<surname><![CDATA[Korelitz]]></surname>
<given-names><![CDATA[B I]]></given-names>
</name>
<name>
<surname><![CDATA[Brensinger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[J D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2005</year>
<volume>54</volume>
<page-range>1121-1125</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feagan]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Fedorak]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Methotrexate for the treatment of Crohn´s disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1995</year>
<volume>332</volume>
<page-range>292-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feagan]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Fedorak]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A comparison of methotrexate with placebo for the maintenance of remission in Crohn´s disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2000</year>
<volume>342</volume>
<page-range>1627-32</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Targan]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Present]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Rutgeerts]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn´s disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1997</year>
<volume>337</volume>
<page-range>1029-35</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Feagan]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Rutgeerts]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Maintenance infliximab for Crohn´s disease: the ACCENT I randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>359</volume>
<page-range>1541-49</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keane]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gershon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wise]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>345</volume>
<page-range>1098-1104</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papadakis]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Shaye]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Targan]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Abreu]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Safety and efficacy of adalimumab (D2E7) in Crohn´s disease patients with an attenuated response to infliximab]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year></year>
<volume>2005</volume>
<numero>100</numero>
<issue>100</issue>
<page-range>75-79</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colombel]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rutgeerts]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Adalimumab for maintenance of clinical response and remission in patients with Crohn´s disease: The CHARM trial]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2007</year>
<volume>132</volume>
<page-range>52-65</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schawrtz]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Pemberton]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diagnosis and treatment of perianal fistulas in Crohn disease]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2001</year>
<volume>135</volume>
<page-range>906-18</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parks]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Hardcastle]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A classification of fistula in ano]]></article-title>
<source><![CDATA[Br J Surg]]></source>
<year>1976</year>
<volume>63</volume>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fazio]]></surname>
<given-names><![CDATA[VW]]></given-names>
</name>
<name>
<surname><![CDATA[Feagan]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[AGA medical position statement: Perianal Crohn Disease]]></article-title>
<source><![CDATA[Gastroenterol]]></source>
<year>2003</year>
<volume>125</volume>
<page-range>1508-30</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[May]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Fick]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Sutherland]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Azathioprine and 6-mercaptopurine in Crohn disease]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1995</year>
<volume>123</volume>
<page-range>132-142</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Present]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Sandler]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tacrolimus for the treatment of fistulas in patients with Crohn´s disease]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2003</year>
<volume>125</volume>
<page-range>380-388</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Present]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Rutgeerts]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Targan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Infliximab for the treatment of fistulas in patients with Crohn´s disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>340</volume>
<page-range>1398-405</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sands]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Rutgeerts]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Infliximab maintenance therapy for fistulizing Crohn´s Disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2004</year>
<volume>350</volume>
<page-range>876-85</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sands]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Blank]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Van Deventer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Maintenance infliximab does not result in increased abscess development in fistulizing Crohn´s disease: results from the ACCENT II study]]></article-title>
<source><![CDATA[Aliment Pharm Ther]]></source>
<year>2006</year>
<volume>23</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1127-36</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Medical Therapy for Ulcerative colitis]]></article-title>
<source><![CDATA[Kirsner´s Inflammatory Bowel Disease]]></source>
<year>2004</year>
<volume>33</volume>
<page-range>503-530</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Systematic review: the pharmacokinetics profiles of oral mesalazine formulations and mesalazine prodrugs used in the management of ulcerative colitis]]></article-title>
<source><![CDATA[Alim Pharmac Ther]]></source>
<year>2003</year>
<volume>17</volume>
<page-range>29-42</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sutherland]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mc Donald]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Oral 5-amonisalicylic acid for maintenance of remission in ulcerative colitis]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2006</year>
<volume>2</volume>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sutherland]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mc Donald]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Oral 5-amonisalicylic acid for induction of remission in ulcerative colitis]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2006</year>
<volume>2</volume>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kane]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Huo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Magnanti]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A Pilot Feasibility Study of Once Daily Versus Conventional Dosing Mesalamine for Maintenance of Ulcerative Colitis]]></article-title>
<source><![CDATA[Clin Gastroen Hepatol]]></source>
<year>2003</year>
<volume>1</volume>
<page-range>170-3</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ajayi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Delayed-release oral mesalamine at 4.8 g/day (800 mg tableta) for the treatment of moderately active ulcerative colitis: The ASCEND trial]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2005</year>
<volume>100</volume>
<page-range>2478-2485</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marteau]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Probert]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Lindaren]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Combined oral and enema treatment with pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2005</year>
<volume>54</volume>
<page-range>960-965</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paoluzi]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Iacopini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pica]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velayos]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Terdiman]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of 5-Aminosalicylate use on colorectal cancer and dysplasia risk: A systematic review and metaanalysis of observational studies]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2005</year>
<volume>100</volume>
<page-range>1345-1353</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Podolsky]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Inflammatory bowel disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>347</volume><volume>6</volume>
<page-range>417-429</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ardizzone]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maconi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bianchi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Randomized controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2006</year>
<volume>55</volume>
<page-range>47-53</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mantzaris]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Petraki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A prospective randomized observer -blind- 2 years trial of azathioprine monotherapy vs azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2004</year>
<volume>99</volume><volume>6</volume>
<page-range>1123-8</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Assche]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[D’Haens]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rutgeerts]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2003</year>
<volume>125</volume>
<page-range>1025-31</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shibolet]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Regushevskaya]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Brezis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soares-Weiser]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cyclosporine A for induction of remission in severe ulcerative colitis]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2005</year>
<volume>1</volume>
</nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D´Haens]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Infliximab for ulcerative colitis: Finally some answers]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2005</year>
<volume>128</volume>
<page-range>2161-2166</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jarnerot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hertervig]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Curman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2005</year>
<volume>128</volume>
<page-range>1805-1811</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rutgeerts]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Feagan]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Infliximab for induction and maintenance therapy for ulcerative colitis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2005</year>
<volume>353</volume>
<page-range>2462-76</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
